How a Dentist's Name Became a Synonym for a Life-saving Device: The Story of Dr. Charles Stent (Journal of the History of Dentistry 200l julio:49 (2). Citado en [1]Arhivirano 2008-12-02 na Wayback Machine-u, Pristupljeno 25. 4. 2013.
bui.ac.uk
Having a Ureteric Stent - What to Expect and How to Manage. Authors: Mr. H. B. Joshi (Specialist Registrar in Urology, Cambridge. Formerly Research Registrar at Bristol Urological Institute), N. Newns (Staff Nurse), Mr. F. X. Keeley Jr. (Consultant Urologist), Mr. A. G. Timoney (Consultant Urologist), Bristol Urological Institute, Southmead Hospital, Westbury-on-trym, Bristol BS10 5NB, Pristupljeno 25. 4. 2013.
doi.org
dx.doi.org
Serruys, PW; Ormiston JA, Onuma Y, et al. (2009-03-14). „A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods”. Lancet373 (9667): 897–910. DOI:10.1016/S0140-6736(09)60325-1. PMID19286089.
(en)Brener SJ. Insights into the pathophysiology of ST-elevation myocardial infarction. Am Heart J. 2006 Jun;151(6 Suppl):S4-10. PubMed, Pristupljeno 25. 4. 2013.
Grüntzig A. Transluminal dilatation of coronaryartery stenosis. Lancet. 1978;1:263. PubMed
Xiaodong Ma, Tim Wu, Michael P Robich, Xingwei Wang, Hao Wu, Bryan Buchholz, and Stephen McCarthy, Drug-eluting stents Int J Clin Exp Med. 2010; 3(3): 192–201. Published online 2010 July 15.
(en)Tanner FC, Boehm M, Akyürek LM, San H, Yang ZY, Tashiro J, Nabel GJ, Nabel EG. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 2000 May 2;101(17):2022-5. PubMed-Abstract , Pristupljeno 25. 4. 2013.
(en)Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Lüscher TF, Tanner FC. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 2000 May 2;101(17):2022-5. PubMed-Abstract, Pristupljeno 25. 4. 2013.
(en)Abal M, Andreu JM, Barasoain I. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Curr Cancer Drug Targets. 2003 Jun;3(3):193-203. PubMed-Abstract, Pristupljeno 25. 4. 2013.
(en)Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008 Jul 29;52(5):333-42. PubMed-Abstract
(en)Waksman R. Biodegradable stents: they do their job and disappear. J Invasive Cardiol. 2006;18:70–74. PubMed-Abstract, Pristupljeno 25. 4. 2013.
Serruys, PW; Ormiston JA, Onuma Y, et al. (2009-03-14). „A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods”. Lancet373 (9667): 897–910. DOI:10.1016/S0140-6736(09)60325-1. PMID19286089.
nlm.nih.gov
Robert A. Cowles Aortic aneurysm repair - endovascular MedlinePlus, Pristupljeno 25. 4. 2013.
Biographic sketch of Andreas Gruentzig. [2] Posećeno 25.01.2011
web.archive.org
How a Dentist's Name Became a Synonym for a Life-saving Device: The Story of Dr. Charles Stent (Journal of the History of Dentistry 200l julio:49 (2). Citado en [1]Arhivirano 2008-12-02 na Wayback Machine-u, Pristupljeno 25. 4. 2013.
